Leukemia & Lymphoma, Volume 64, Issue 2 (2023)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Leukemia & Lymphoma, Volume 64, Issue 2 (2023)

See all volumes and issues
Vol 65, 2024 Volume 64, 2023 Vol 63, 2022 Vol 62, 2021 Vol 61, 2020 Vol 60, 2019 Vol 59, 2018 Vol 58, 2017 Vol 57, 2016 Vol 56, 2015 Vol 55, 2014 Vol 54, 2013 Vol 53, 2012 Vol 52, 2011 Vol 51, 2010 Vol 50, 2009 Vol 49, 2008 Vol 48, 2007 Vol 47, 2006 Vol 46, 2005 Vol 45, 2004 Vol 44, 2003 Vol 43, 2002 Vol 42, 2001 Vol 41, 2001 Vol 40, 2000-2001 Vol 39, 2000 Vol 38, 2000 Vol 37, 2000 Vol 36, 1999-2000 Vol 35, 1999 Vol 34, 1999 Vol 33, 1999 Vol 32, 1998-1999 Vol 31, 1998 Vol 30, 1998 Vol 29, 1998 Vol 28, 1997-1998 Vol 27, 1997 Vol 26, 1997 Vol 25, 1997 Vol 24, 1996-1997 Vol 23, 1996 Vol 22, 1996 Vol 21, 1996 Vol 20, 1995-1996 Vol 19, 1995 Vol 18, 1995 Vol 17, 1995 Vol 16, 1995 Vol 15, 1995 Vol 16, 1995 Vol 15, 1995 Vol 14, 1994 Vol 13, 1994 Vol 12, 1993-1994 Vol 11, 1993 Vol 10, 1993 Vol 9, 1993 Vol 8, 1992 Vol 7, 1992 Vol 6, 1991-1992 Vol 5, 1991 Vol 4, 1991 Vol 3, 1990-1991 Vol 2, 1990 Vol 1, 1989-1990
Download citations Download PDFs

Commentary

Article Commentary
Putting the brain into mantle cell lymphoma
Chiara Rusconi & Carlo Visco
Pages: 259-260
Published online: 02 Jan 2023
CitationforPutting the brain into mantle cell lymphoma | Full Text | References | PDF (455.6 KB) | EPUB
  • 136 Views
  • 0 CrossRef citations
  • 0Altmetric

Reviews

Review
The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
Mohammed Alomari, Chutima Kunacheewa & Elisabet E. Manasanch
Pages: 261-272
Published online: 25 Oct 2022
AbstractforThe role of soluble B cell maturation antigen as a biomarker in multiple myeloma | Full Text | References | PDF (1.4 MB) | EPUB
  • 291 Views
  • 2 CrossRef citations
  • 0Altmetric
Review
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review
Moazzam Shahzad, Sibgha Gull Chaudhary, Ezza Tariq, Ali Hassan Mushtaq, Iqra Anwar, Nausheen Ahmed, Rajat Bansal, Forat Lutfi, Ramesh Balusu, Haitham Abdelhakim, Abdulraheem Yacoub, Peiman Hematti, Anurag K. Singh, Joseph P. McGuirk & Muhammad Umair Mushtaq
Pages: 273-282
Published online: 25 Oct 2022
AbstractforUse of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review | Full Text | References | PDF (1.3 MB) | EPUB
  • 170 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
From mechanism to resistance – changes in the use of dexamethasone in the treatment of multiple myeloma
Aaron S. Rosenberg
Pages: 283-291
Published online: 28 Oct 2022
AbstractforFrom mechanism to resistance – changes in the use of dexamethasone in the treatment of multiple myeloma | Full Text | References | PDF (985.6 KB) | EPUB
  • 3505 Views
  • 2 CrossRef citations
  • 0Altmetric
Open Access
Review
JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options
Brady L. Stein
Pages: 292-299
Published online: 27 Oct 2022
AbstractforJAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options | Full Text | References | PDF (750.1 KB) | EPUB
  • 424 Views
  • 2 CrossRef citations
  • 0Altmetric

Articles

Article
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection
Kurt S. Bantilan, Neil E. Kay, Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, Jose F. Leis, Wei Ding, Susan L. Slager, Jacob D. Soumerai, Lindsey E. Roeker, Anthony Mato & Andrew D. Zelenetz
Pages: 300-311
Published online: 12 Dec 2022
AbstractforTime to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection | Full Text | References | PDF (2.3 MB) | EPUB | Supplemental
  • 223 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program
Stephen P. Mulligan, Stephen Opat, Chan Y. Cheah, Bryone Kuss, Mark Hertzberg, Paula Marlton, Sarah Poplar, Andrea Puig, Marija McGeachie, Robert Weinkove & Constantine S. Tam
Pages: 312-318
Published online: 24 Nov 2022
AbstractforReal-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program | Full Text | References | PDF (1.6 MB) | EPUB | Supplemental
  • 1821 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Article
Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study
Georgia S. Mills, Pietro R. Di Ciaccio, Catherine Tang, Verity Chadwick, Kylie D. Mason, Belinda A. Campbell, Michael J. Shipton, Mohamed Shanavas, Kirk L. Morris, Matthew Greenwood, Jenna Langfield, Giselle Kidson-Gerber, Renee Eslick, Xavier Badoux, Costas K. Yannakou, Shane A. Gangatharan, Ian Bilmon & Nada Hamad
Pages: 319-328
Published online: 24 Nov 2022
AbstractforCapturing the lived experiences of women with lymphoma in pregnancy: a qualitative study | Full Text | References | PDF (1.9 MB) | EPUB
  • 282 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies
Bilal Tariq, Ying C. Ou, Jennifer C. Stern, Vaibhav Mundra, Nicole Wong Doo, Patricia Walker, Katharine L. Lewis, Chester Lin, William Novotny, Srikumar Sahasranaman & Stephen Opat
Pages: 329-338
Published online: 08 Dec 2022
AbstractforA phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies | Full Text | References | PDF (1.2 MB) | EPUB | Supplemental
  • 2110 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Article
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort study using CMS 100% Medicare claims database
Hongbo Yang, Vamsi Bollu, Stephen Lim, Mimi Tesfaye, Anand A. Dalal, Angela Lax, Sakshi Sethi & Jing Zhao
Pages: 339-348
Published online: 21 Nov 2022
AbstractforHealthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort study using CMS 100% Medicare claims database | Full Text | References | PDF (1.6 MB) | EPUB | Supplemental
  • 2084 Views
  • 4 CrossRef citations
  • 0Altmetric
Open Access
Article
Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data
Cecilie E Kiserud, Sandra Lockmer, Idun Baerug, Alv A Dahl, Eva Kimby & Bjørn Østenstad
Pages: 349-355
Published online: 07 Nov 2022
AbstractforHealth-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data | Full Text | References | PDF (616.4 KB) | EPUB
  • 1073 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Article
Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era
Jordan B. Fenlon, Ryan J. Hutten, Skyler B. Johnson, Boyu Hu, Harsh Shah, Deborah M. Stephens, Amit Maity, David K. Gaffney & Randa Tao
Pages: 356-363
Published online: 21 Nov 2022
AbstractforEvaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era | Full Text | References | PDF (1 MB) | EPUB
  • 126 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time
Kedar Kirtane, Maija Reblin, Laura B. Oswald, Nathaly Irizarry-Arroyo, Rachael McCormick, Frederick L. Locke & Dana Ketcher
Pages: 364-370
Published online: 23 Nov 2022
AbstractforPsychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time | Full Text | References | PDF (1.2 MB) | EPUB
  • 177 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Central nervous system involvement by mantle cell lymphoma
Nicole McLaughlin, Yucai Wang, Thomas Witzig, Jose Villasboas, Thomas Habermann, David Inwards, Nora Bennani, Gita Thanarajasingam, Grzegorz Nowakowski, Luis Porrata, Carrie Thompson, Ivana Micallef, Patrick Johnston, Stephen Ansell & Jonas Paludo
Pages: 371-377
Published online: 23 Nov 2022
AbstractforCentral nervous system involvement by mantle cell lymphoma | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 487 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome
Lalit Kumar, Ranjit Kumar Sahoo, Sudhir Kumar, Annie K. Baa, Ghazal Tansir, Neha Pathak, Prabhat S. Malik, Om Dutt Sharma, Anisha Mathew, Ankit Jha, Ritu Gupta, Atul Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Soumyaranjan Malik, Ashish Dutt & for AIIMS Myeloma Group
Pages: 378-387
Published online: 23 Nov 2022
AbstractforAutologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome | Full Text | References | PDF (1 MB) | EPUB | Supplemental
  • 199 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: a retrospective cohort study
Motiur Rahman, Alissa Keegan, Jazmine Mateus & Christopher Kim
Pages: 388-397
Published online: 12 Nov 2022
AbstractforReal-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: a retrospective cohort study | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 1242 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study
Peter Feng Wang, Christopher W. Yee, Boris Gorsh, Miriam L. Zichlin, Prani Paka, Rachel H. Bhak, Natalie Boytsov, Anamika Khanal, Ahmed Noman, Maral DerSarkissian, Shannon Ferrante & Mei Sheng Duh
Pages: 398-406
Published online: 21 Nov 2022
AbstractforTreatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 3554 Views
  • 6 CrossRef citations
  • 0Altmetric
Open Access
Article
Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma
Anisa Bici, Matthew J. Pianko & Victoria R. Nachar
Pages: 407-414
Published online: 29 Oct 2022
AbstractforIncidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma | Full Text | References | PDF (857.8 KB) | EPUB
  • 267 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison
Kelly A. Hyland, Sarah L. Eisel, Aasha I. Hoogland, James C. Root, Kris Bowles, Brian James, Ashley M. Nelson, Margaret Booth-Jones, Paul B. Jacobsen, Tim A. Ahles, Heather S.L Jim & Brian D. Gonzalez
Pages: 415-423
Published online: 07 Dec 2022
AbstractforCognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison | Full Text | References | PDF (1.5 MB) | EPUB
  • 271 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands
Geneviève I.C.G. Ector, Inge G. P. Geelen, Avinash G. Dinmohamed, Mels Hoogendoorn, Peter E. Westerweel, Rosella P.M.G. Hermens & Nicole M.A. Blijlevens
Pages: 424-432
Published online: 11 Nov 2022
AbstractforAdherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands | Full Text | References | PDF (1.6 MB) | EPUB | Supplemental
  • 1184 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Article
Histological diagnosis of acute graft-versus-host disease in different sites of the upper gastrointestinal tract with correlation to endoscopic findings
Andreas Kreft, Lisa Schulze, Isabelle Ries, Mario Schindeldecker & Helmut Neumann
Pages: 433-439
Published online: 06 Nov 2022
AbstractforHistological diagnosis of acute graft-versus-host disease in different sites of the upper gastrointestinal tract with correlation to endoscopic findings | Full Text | References | PDF (1.8 MB) | EPUB
  • 192 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft
Julia McClelland, Eric Wong & Andrew Grigg
Pages: 440-444
Published online: 11 Nov 2022
AbstractforOptimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft | Full Text | References | PDF (433.5 KB) | EPUB
  • 120 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
External validation of a heart failure risk score in patients with acute myeloid leukemia
Peter G. Doukas, Gregory J. Cascino, Zhiying Meng, Abigail S. Baldridge, Yu Kang, Marielle Scherrer-Crosbie & Nausheen Akhter
Pages: 445-453
Published online: 04 Nov 2022
AbstractforExternal validation of a heart failure risk score in patients with acute myeloid leukemia | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 144 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
Jan Philipp Bewersdorf, Kishan K. Patel, George Goshua, Rory M. Shallis, Nikolai A. Podoltsev, Maximilian Stahl, Eytan M. Stein, Scott F. Huntington & Amer M. Zeidan
Pages: 454-461
Published online: 09 Dec 2022
AbstractforCost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia | Full Text | References | PDF (1.5 MB) | EPUB | Supplemental
  • 264 Views
  • 2 CrossRef citations
  • 0Altmetric

Letters to the Editor

Letter to the Editor
Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship with aberrant cytoplasmic CD3 expression
Yan Chen Wongworawat, Ghazaleh Eskandari, Amos Gaikwad, Andrea N. Marcogliese, Lizmery S. Ferguson, Julienne Brackett, Jyotinder N. Punia, M. Tarek Elghetany, Reshma Kulkarni, Pulivarthi H. Rao, Jo Ringrose, Dolores H. Lopez-Terrada, Angshumoy Roy, Choladda V. Curry & Kevin E. Fisher
Pages: 462-467
Published online: 08 Nov 2022
First Page PreviewforFrequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship with aberrant cytoplasmic CD3 expression | Full Text | References | PDF (2 MB) | EPUB | Supplemental
  • 248 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter to the Editor
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study
Hareth Nahi, Saad Z. Usmani, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari & Philippe Moreau
Pages: 468-472
Published online: 02 Jan 2023
First Page PreviewforCorticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study | Full Text | References | PDF (738.2 KB) | EPUB | Supplemental
  • 1764 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Letter to the Editor
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Cheema, Kendra L. Sweet, Adam S. Asch, Jijun (Jane) Liu, Anna B. Moseley, Tracy Maher, Laura L. Kingsbury, Min Fang, Jerald Radich, Richard F. Little & Harry P. Erba
Pages: 473-477
Published online: 14 Dec 2022
First Page PreviewforA randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612 | Full Text | References | PDF (835.4 KB) | EPUB | Supplemental
  • 566 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter to the Editor
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients
Nadine Kutsch, Emily Eva Holmes, Sandra Robrecht, Gudrun Schüler, Ursula Vehling-Kaiser, Thomas Decker, Sigrun Müller-Hagen, Karin Heinisch, Sebastian Böttcher, Matthias Ritgen, Karl-Anton Kreuzer, Stephan Stilgenbauer, Anna Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek & Clemens-Martin Wendtner
Pages: 478-482
Published online: 24 Nov 2022
First Page PreviewforEfficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients | Full Text | References | PDF (482.8 KB) | EPUB | Supplemental
  • 144 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter to the Editor
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings
Sabina Chiaretti, Akram Taherinasab, Irene Della Starza, Martina Canichella, Michela Ansuinelli, Maria Stefania De Propris, Monica Messina, Orietta Spinelli, Alessandra Santoro, Lucia Anna De Novi, Deborah Cardinali, Mattia Schipani, Valentina Arena, Renato Bassan, Anna Guarini & Robin Foà
Pages: 483-486
Published online: 19 Dec 2022
First Page PreviewforZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings | Full Text | References | PDF (854.4 KB) | EPUB | Supplemental
  • 1358 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Letter to the Editor
First clinical description of a pedigree with complete NAF1 deletion
Jean Galtier, Sophie Dimicoli-Salazar, Aurélien Trimouille, Elodie Lainey, Patrick Revy, Audrey Bidet, Yoann Vial, Edouard Forcade, Marie-Laure Negrier-Leibreich, Etienne Rivière, Julie Tinat, Nathalie Le Meur, Christelle Ménard, Arnaud Pigneux, Thibaut Leguay, Pierre-Yves Dumas, Ba Ibrahima & Caroline Kannengiesser
Pages: 487-490
Published online: 23 Nov 2022
First Page PreviewforFirst clinical description of a pedigree with complete NAF1 deletion | Full Text | References | PDF (815.7 KB) | EPUB
  • 142 Views
  • 0 CrossRef citations
  • 0Altmetric
Letter to the Editor
Organ toxicities associated with chimeric antigen receptor T-cell therapy
Mary McGann, Kelly J. Gaffney, James A. Davis, Deidra Smith & Hamza Hashmi
Pages: 491-494
Published online: 23 Nov 2022
First Page PreviewforOrgan toxicities associated with chimeric antigen receptor T-cell therapy | Full Text | References | PDF (575.5 KB) | EPUB
  • 130 Views
  • 0 CrossRef citations
  • 0Altmetric
Letter to the Editor
Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy
Chengyuan Gu, Qian Wu, Jingren Zhang, Liqing Kang, Lei Yu, Huiying Qiu, Depei Wu, Suning Chen & Xiaofei Yang
Pages: 495-498
Published online: 17 Nov 2022
First Page PreviewforSuccessful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy | Full Text | References | PDF (623.7 KB) | EPUB
  • 220 Views
  • 3 CrossRef citations
  • 0Altmetric
Letter to the Editor
Morphology and clinical characteristics of a case of FIP1L1-RARA fusion-associated variant acute promyelocytic leukemia
Xiangyan Feng, Yizhou Zheng & Junqing Xu
Pages: 499-502
Published online: 09 Nov 2022
First Page PreviewforMorphology and clinical characteristics of a case of FIP1L1-RARA fusion-associated variant acute promyelocytic leukemia | Full Text | References | PDF (642.9 KB) | EPUB
  • 883 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Letter to the Editor
Imaging minimal residual disease evaluation in multiple myeloma using [18F]FDG PET/MRI
Gregorio Barilà, Filippo Crimì, Massimiliano Arangio Febbo, Laura Pavan, Susanna Vedovato, Giulio Cabrelle, Chiara Zanon, Cristina Campi, Diego Cecchin, Pietro Zucchetta, Carmelo Lacognata, Gianpietro Semenzato & Renato Zambello
Pages: 503-506
Published online: 16 Nov 2022
First Page PreviewforImaging minimal residual disease evaluation in multiple myeloma using [18F]FDG PET/MRI | Full Text | References | PDF (832.1 KB) | EPUB
  • 137 Views
  • 0 CrossRef citations
  • 0Altmetric
Letter to the Editor
Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series
Daria Gaut, Caspian Oliai & Monica Mead
Pages: 507-510
Published online: 17 Jan 2023
First Page PreviewforOutcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series | Full Text | References | PDF (368 KB) | EPUB
  • 164 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia
Jennifer Marvin-Peek et al.
Article | Published online: 15 May 2024
Mitigating time toxicity in lymphoma and multiple myeloma
Mengyang Di et al.
Review Article | Published online: 15 May 2024
Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure
Fabien Despas et al.
Letter to the Editor | Published online: 15 May 2024
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry
Paul Wadsworth et al.
Letter to the Editor | Published online: 15 May 2024
View all latest articles